-
公开(公告)号：US11850274B2
公开(公告)日：2023-12-26
申请号：US17238943
申请日：2021-04-23
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens Fritsche , Toni Weinschenk , Steffen Walter , Peter Lewandrowski , Harpreet Singh
CPC classification number: A61K38/1709 , A61K39/0011 , A61P35/00 , C07K7/06 , G01N33/505 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , C07K2319/00
Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号：US11685769B2
公开(公告)日：2023-06-27
申请号：US17366837
申请日：2021-07-02
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette Song , Franziska Hoffgaard , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
IPC: C07K14/47 , A61P35/02 , A61P35/00 , A61K39/00 , A61K35/17 , A61K45/06 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/115
CPC classification number: C07K14/4748 , A61K35/17 , A61K39/0011 , A61K39/001186 , A61K39/001193 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/7051 , C07K14/70539 , C07K16/2833 , C07K16/30 , C07K16/303 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C12N5/0636 , C12N15/115 , C07K2319/00 , C12N2310/16
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11679147B2
公开(公告)日：2023-06-20
申请号：US17853344
申请日：2022-06-29
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC: A61K35/17 , A61K39/00 , A61K38/04 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , G01N33/68 , A61K51/10 , A61K35/12
CPC classification number: A61K39/00111 , A61K35/17 , A61K38/04 , A61K39/0011 , A61K51/1057 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , G01N33/6803 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998
Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVLPGLVGV (SEQ ID NO: 56), in which the peptide is in a complex with an MHC molecule.
-
公开(公告)号：US11667685B2
公开(公告)日：2023-06-06
申请号：US17929465
申请日：2022-09-02
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette Song , Heiko Schuster , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
IPC: C07K14/47 , A61K35/17 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12Q1/6886 , C07K7/04 , A61K38/08 , C07K7/06 , G16B25/10
CPC classification number: C07K14/4748 , A61K35/17 , A61K39/0011 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12Q1/6886 , A61K38/08 , C07K7/04 , C07K7/06 , C07K2319/00 , C07K2319/55 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G16B25/10
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
25.发明授权公开(公告)号：US11655280B2
公开(公告)日：2023-05-23
申请号：US17738453
申请日：2022-05-06
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko Schuster , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh , Gisela Schimmack , Michael Roemer
IPC: C07K14/725 , C12N5/0783 , A61P35/00 , C07K16/28 , C07K14/74 , A61K35/17 , A61K39/00 , A61K38/00 , G01N33/574 , A61K9/19 , G16B25/10 , C12N15/115
CPC classification number: C07K14/7051 , A61K9/19 , A61K35/17 , A61K39/001111 , A61P35/00 , C07K14/70539 , C07K16/2809 , C07K16/2833 , C12N5/0638 , C12N15/115 , G01N33/57492 , G16B25/10 , A61K38/00 , C07K2319/00 , C12N2310/16
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
公开(公告)号：US11648292B2
公开(公告)日：2023-05-16
申请号：US17733260
申请日：2022-04-29
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens Fritsche , Toni Weinschenk , Steffen Walter , Peter Lewandrowski , Harpreet Singh
CPC classification number: A61K38/1709 , A61K39/0011 , A61P35/00 , C07K7/06 , G01N33/505 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , C07K2319/00
Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号：US11607446B2
公开(公告)日：2023-03-21
申请号：US17165638
申请日：2021-02-02
Applicant: Immatics Biotechnologies GmbH
Inventor： Sabrina Kuttruff-Coqui , Toni Weinschenk , Jens Fritsche , Steffen Walter , Norbert Hilf , Oliver Schoor , Colette Song , Harpreet Singh
IPC: A61K39/00 , A61K38/17 , C07K14/47 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/74 , C07K16/28 , C12Q1/6886
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
28.发明授权公开(公告)号：US11603397B2
公开(公告)日：2023-03-14
申请号：US17743771
申请日：2022-05-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko Schuster , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh , Gisela Schimmack , Michael Roemer
IPC: C07K14/725 , C12N5/0783 , A61P35/00 , G01N33/574 , C07K16/28 , C07K14/74 , A61K35/17 , A61K39/00 , A61K38/00 , A61K9/19 , G16B25/10 , C12N15/115
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11524059B2
公开(公告)日：2022-12-13
申请号：US17852205
申请日：2022-06-28
Applicant: Immatics Biotechnologies GmbH
Inventor： Sabrina Kuttruff-Coqui , Toni Weinschenk , Jens Fritsche , Steffen Walter , Norbert Hilf , Oliver Schoor , Colette Song , Harpreet Singh
IPC: C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , A61P35/02 , A61P35/00 , A61K35/17 , A61K39/00 , C12N5/0783 , C07K14/705 , C07K7/06 , C07K7/08 , C12Q1/6886
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US11414472B2
公开(公告)日：2022-08-16
申请号：US17587387
申请日：2022-01-28
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette Song , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
IPC: A61K39/00 , C07K14/47 , C07K14/74 , C07K16/30 , C07K14/725 , C12N5/0783 , C12N15/10 , C12N15/115 , G01N33/574 , A61P35/00 , C07K16/28 , A61K35/17 , C07K7/06 , C07K14/54 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
618
records
(took 0.024 seconds)
